UY29445A1 - Composiciones para la transmisión transmucosa oral de la metformina - Google Patents

Composiciones para la transmisión transmucosa oral de la metformina

Info

Publication number
UY29445A1
UY29445A1 UY29445A UY29445A UY29445A1 UY 29445 A1 UY29445 A1 UY 29445A1 UY 29445 A UY29445 A UY 29445A UY 29445 A UY29445 A UY 29445A UY 29445 A1 UY29445 A1 UY 29445A1
Authority
UY
Uruguay
Prior art keywords
compositions
oral
transmuctive
metformin
transmission
Prior art date
Application number
UY29445A
Other languages
English (en)
Spanish (es)
Inventor
Anna E Gluskun
Muhammad Waseem T Qazi
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of UY29445A1 publication Critical patent/UY29445A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY29445A 2005-03-30 2006-03-29 Composiciones para la transmisión transmucosa oral de la metformina UY29445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66647505P 2005-03-30 2005-03-30

Publications (1)

Publication Number Publication Date
UY29445A1 true UY29445A1 (es) 2006-10-02

Family

ID=37052910

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29445A UY29445A1 (es) 2005-03-30 2006-03-29 Composiciones para la transmisión transmucosa oral de la metformina

Country Status (16)

Country Link
US (1) US20090069437A1 (enExample)
EP (1) EP1863465A4 (enExample)
JP (1) JP2008534523A (enExample)
AR (1) AR052960A1 (enExample)
AU (1) AU2006228949A1 (enExample)
BR (1) BRPI0611555A2 (enExample)
CA (1) CA2603450A1 (enExample)
CR (1) CR9363A (enExample)
IL (1) IL185931A0 (enExample)
MX (1) MX2007012047A (enExample)
NZ (1) NZ560990A (enExample)
PE (1) PE20061245A1 (enExample)
RU (2) RU2409357C2 (enExample)
UY (1) UY29445A1 (enExample)
WO (1) WO2006102752A1 (enExample)
ZA (1) ZA200708834B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080025A1 (en) * 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum comprising metformin
WO2009090210A2 (en) * 2008-01-16 2009-07-23 Janssen Pharmaceutica Nv Combination of metformin and an mtp inhibitor
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
CN102316872B (zh) * 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
EP2445494A4 (en) * 2009-06-24 2012-12-12 Univ Koebenhavn TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
WO2013063526A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EP3696281A1 (en) * 2019-02-13 2020-08-19 Johann Wolfgang Goethe-Universität Frankfurt am Main Arginase as biomarker and drug target for pcos
WO2020227344A1 (en) * 2019-05-06 2020-11-12 The Regents Of The University Of California Chloride intracellular channel 1 for regulation of food intake

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161428C (da) * 1985-05-10 1991-12-16 Fertin Lab As Fast, oralt cariesmodvirkende middel
DK365389D0 (da) * 1989-07-24 1989-07-24 Fertin Lab As Antifungalt tyggegummipraeparat
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
WO1999055320A1 (en) * 1998-04-29 1999-11-04 Sumitomo Pharmaceuticals Co., Ltd. Oral formulation comprising biguanide and an organic acid
DK0974356T3 (da) * 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6344222B1 (en) * 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
BR0115390A (pt) * 2000-11-03 2004-02-25 Andrx Corp Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
KR20100137023A (ko) * 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
WO2005041926A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid

Also Published As

Publication number Publication date
RU2007139886A (ru) 2009-05-10
JP2008534523A (ja) 2008-08-28
RU2010139163A (ru) 2012-03-27
US20090069437A1 (en) 2009-03-12
AU2006228949A1 (en) 2006-10-05
BRPI0611555A2 (pt) 2010-09-21
EP1863465A1 (en) 2007-12-12
ZA200708834B (en) 2008-11-26
WO2006102752A1 (en) 2006-10-05
NZ560990A (en) 2009-02-28
RU2409357C2 (ru) 2011-01-20
MX2007012047A (es) 2007-12-12
CR9363A (es) 2008-02-12
IL185931A0 (en) 2008-02-09
EP1863465A4 (en) 2010-12-15
AR052960A1 (es) 2007-04-11
PE20061245A1 (es) 2007-01-06
CA2603450A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
CR9363A (es) Composiciones para la transmision transmucosa oral de la metformina
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
GT200400239A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
PA8591701A1 (es) Derivados de pirrolopirimidina
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
NO20090175L (no) Stabile laquinimod sammensetninger
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
CL2007001915A1 (es) Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras.
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
BRPI0607897A2 (pt) compostos oxindol e sua utilização como agentes terapêuticos
CL2007003832A1 (es) Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
CR8220A (es) Composicion de fexofenadina y proceso para su preparacion
NO20075111L (no) Farmasoytisk sammensetning
BRPI0517701A (pt) uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
AR109263A2 (es) Composición que comprende moxidectina
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
NO20076405L (no) Anvendelse av 24-nor-UDCA
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
PA8547801A1 (es) Microcápsula para la protección frente al mal aliento

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160815